Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring orthopedic ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...

exenatide, which was published in The Lancet in 2017. “This cumulative clinical data […] strongly supports the earlier laboratory and epidemiological data, that GLP-1 receptor stimulation in ...

When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Verde Resources, Inc. announces groundbreaking preliminary findings from the National Center for Asphalt Technology (NCAT), revealing the transformative impact of its TerraZyme® technology in road ...